COVID-19 Impact on Chronic Myeloid Leukemia Patients

(1) Background: Chronic myeloid leukemia (CML) is a blood dyscrasia that accounts for about 20% of all leukemia cases. Tyrosine kinase inhibitors (TKIs) are used as first line treatment of CML. The 2019 SARS-CoV-2 outbreak raised new concerns for CML patients, such as whether CML increases the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbore, Dana Raluca, Galdean, Simona Maria, Dima, Delia, Rus, Ioana, Kegyes, David, Ababei, Raluca Geanina, Dragancea, Daniela, Tomai, Radu Andrei, Trifa, Adrian Pavel, Tomuleasa, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699250/
https://www.ncbi.nlm.nih.gov/pubmed/36573722
http://dx.doi.org/10.3390/jpm12111886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699250/
https://www.ncbi.nlm.nih.gov/pubmed/36573722
http://dx.doi.org/10.3390/jpm12111886

Ejemplares similares